Gillmeyer KR, Rinne ST, Glickman ME, et al. - Researchers investigated whether an increased risk for subsequently receiving potentially inappropriate prescriptions in Veterans Health Administration (VA) may exist in veterans with group 2/3 pulmonary hypertension (PH) initiated on phosphodiesterase-5 inhibitors (PDE5i) treatment via Medicare. For this purpose, factors related to prescribing of PDE5i for group 2/3 PH were determined. This study involved 34,775 Medicare-eligible veterans with group 2/3 PH. Backing the primary hypothesis, prior treatment through Medicare was identified as the variable most strongly related to PDE5i therapy in VA for group 2/3 PH. More severe disease as suggested by recent right heart failure or respiratory failure and prior right heart catheterization were documented as other variables that were strongly related to increased probability of VA treatment. These observations indicate a missed opportunity to reevaluate treatment suitability when PH patients seek prescriptions from VA, this revelation holds relevance given policies encouraging shared care across VA and community settings. There is a necessity for interventions to strengthen awareness that group 2/3 PH patients are unlikely to derive benefit from pulmonary vasodilators and instead may suffer harm.